SCHEMBL13952183

SCHEMBL13952183

CC1CCCC[C@@H]1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.62
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
MEN1 O00255 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
PEPD P12955 1/20 0.40
ALDH1A1 P00352 2/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL791505 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL265072 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL10556768 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL301766 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL3382944 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL265657 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL9885352 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL11930055 1.00 EPHX1 (0.62) EPHX1CA1CA2CA4MEN1
SCHEMBL6917395 0.97 EPHX1 (0.60) EPHX1CA1CA2CA4MEN1
SCHEMBL12529955 0.97 EPHX1 (0.60) EPHX1CA1CA2CA4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054472-A1 Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof TEIJIN PHARMA LIMITED (JP) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054472-A1 Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof MAPKAPK2, MAPKAPK5, MAPKAPK3 EPHX1 3501/4885CA1 2793/4885CA2 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.